Cargando…
Huangqin decoction alleviates lipid metabolism disorders and insulin resistance in nonalcoholic fatty liver disease by triggering Sirt1/NF-κB pathway
BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is a clinicopathological entity characterized by intrahepatic ectopic steatosis. As a consequence of increased consumption of high-calorie diet and adoption of a sedentary lifestyle, the incidence of NAFLD has surpassed that of viral hepatitis, ma...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10473922/ https://www.ncbi.nlm.nih.gov/pubmed/37664157 http://dx.doi.org/10.3748/wjg.v29.i31.4744 |
_version_ | 1785100378383056896 |
---|---|
author | Yan, Bao-Fei Pan, Lan-Fen Quan, Yi-Fang Sha, Qian Zhang, Jing-Zheng Zhang, Yi-Feng Zhou, Li-Bing Qian, Xi-Long Gu, Xiao-Mei Li, Feng-Tao Wang, Ting Liu, Jia Zheng, Xian |
author_facet | Yan, Bao-Fei Pan, Lan-Fen Quan, Yi-Fang Sha, Qian Zhang, Jing-Zheng Zhang, Yi-Feng Zhou, Li-Bing Qian, Xi-Long Gu, Xiao-Mei Li, Feng-Tao Wang, Ting Liu, Jia Zheng, Xian |
author_sort | Yan, Bao-Fei |
collection | PubMed |
description | BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is a clinicopathological entity characterized by intrahepatic ectopic steatosis. As a consequence of increased consumption of high-calorie diet and adoption of a sedentary lifestyle, the incidence of NAFLD has surpassed that of viral hepatitis, making it the most common cause of chronic liver disease globally. Huangqin decoction (HQD), a Chinese medicinal formulation that has been used clinically for thousands of years, has beneficial outcomes in patients with liver diseases, including NAFLD. However, the role and mechanism of action of HQD in lipid metabolism disorders and insulin resistance in NAFLD remain poorly understood. AIM: To evaluate the ameliorative effects of HQD in NAFLD, with a focus on lipid metabolism and insulin resistance, and to elucidate the underlying mechanism of action. METHODS: High-fat diet-induced NAFLD rats and palmitic acid (PA)-stimulated HepG2 cells were used to investigate the effects of HQD and identify its potential mechanism of action. Phytochemicals in HQD were analyzed by high-performance liquid chromatography (HPLC) to identify the key components. RESULTS: Ten primary chemical components of HQD were identified by HPLC analysis. In vivo, HQD effectively prevented rats from gaining body and liver weight, improved the liver index, ameliorated hepatic histological aberrations, decreased transaminase and lipid profile disorders, and reduced the levels of pro-inflammatory factors and insulin resistance. In vitro studies revealed that HQD effectively alleviated PA-induced lipid accumulation, inflammation, and insulin resistance in HepG2 cells. In-depth investigation revealed that HQD triggers Sirt1/NF-κB pathway-modulated lipogenesis and inflammation, contributing to its beneficial actions, which was further corroborated by the addition of the Sirt1 antagonist EX-527 that compromised the favorable effects of HQD. CONCLUSION: In summary, our study confirmed that HQD mitigates lipid metabolism disorders and insulin resistance in NAFLD by triggering the Sirt1/NF-κB pathway. |
format | Online Article Text |
id | pubmed-10473922 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-104739222023-09-03 Huangqin decoction alleviates lipid metabolism disorders and insulin resistance in nonalcoholic fatty liver disease by triggering Sirt1/NF-κB pathway Yan, Bao-Fei Pan, Lan-Fen Quan, Yi-Fang Sha, Qian Zhang, Jing-Zheng Zhang, Yi-Feng Zhou, Li-Bing Qian, Xi-Long Gu, Xiao-Mei Li, Feng-Tao Wang, Ting Liu, Jia Zheng, Xian World J Gastroenterol Basic Study BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is a clinicopathological entity characterized by intrahepatic ectopic steatosis. As a consequence of increased consumption of high-calorie diet and adoption of a sedentary lifestyle, the incidence of NAFLD has surpassed that of viral hepatitis, making it the most common cause of chronic liver disease globally. Huangqin decoction (HQD), a Chinese medicinal formulation that has been used clinically for thousands of years, has beneficial outcomes in patients with liver diseases, including NAFLD. However, the role and mechanism of action of HQD in lipid metabolism disorders and insulin resistance in NAFLD remain poorly understood. AIM: To evaluate the ameliorative effects of HQD in NAFLD, with a focus on lipid metabolism and insulin resistance, and to elucidate the underlying mechanism of action. METHODS: High-fat diet-induced NAFLD rats and palmitic acid (PA)-stimulated HepG2 cells were used to investigate the effects of HQD and identify its potential mechanism of action. Phytochemicals in HQD were analyzed by high-performance liquid chromatography (HPLC) to identify the key components. RESULTS: Ten primary chemical components of HQD were identified by HPLC analysis. In vivo, HQD effectively prevented rats from gaining body and liver weight, improved the liver index, ameliorated hepatic histological aberrations, decreased transaminase and lipid profile disorders, and reduced the levels of pro-inflammatory factors and insulin resistance. In vitro studies revealed that HQD effectively alleviated PA-induced lipid accumulation, inflammation, and insulin resistance in HepG2 cells. In-depth investigation revealed that HQD triggers Sirt1/NF-κB pathway-modulated lipogenesis and inflammation, contributing to its beneficial actions, which was further corroborated by the addition of the Sirt1 antagonist EX-527 that compromised the favorable effects of HQD. CONCLUSION: In summary, our study confirmed that HQD mitigates lipid metabolism disorders and insulin resistance in NAFLD by triggering the Sirt1/NF-κB pathway. Baishideng Publishing Group Inc 2023-08-21 2023-08-21 /pmc/articles/PMC10473922/ /pubmed/37664157 http://dx.doi.org/10.3748/wjg.v29.i31.4744 Text en ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. |
spellingShingle | Basic Study Yan, Bao-Fei Pan, Lan-Fen Quan, Yi-Fang Sha, Qian Zhang, Jing-Zheng Zhang, Yi-Feng Zhou, Li-Bing Qian, Xi-Long Gu, Xiao-Mei Li, Feng-Tao Wang, Ting Liu, Jia Zheng, Xian Huangqin decoction alleviates lipid metabolism disorders and insulin resistance in nonalcoholic fatty liver disease by triggering Sirt1/NF-κB pathway |
title | Huangqin decoction alleviates lipid metabolism disorders and insulin resistance in nonalcoholic fatty liver disease by triggering Sirt1/NF-κB pathway |
title_full | Huangqin decoction alleviates lipid metabolism disorders and insulin resistance in nonalcoholic fatty liver disease by triggering Sirt1/NF-κB pathway |
title_fullStr | Huangqin decoction alleviates lipid metabolism disorders and insulin resistance in nonalcoholic fatty liver disease by triggering Sirt1/NF-κB pathway |
title_full_unstemmed | Huangqin decoction alleviates lipid metabolism disorders and insulin resistance in nonalcoholic fatty liver disease by triggering Sirt1/NF-κB pathway |
title_short | Huangqin decoction alleviates lipid metabolism disorders and insulin resistance in nonalcoholic fatty liver disease by triggering Sirt1/NF-κB pathway |
title_sort | huangqin decoction alleviates lipid metabolism disorders and insulin resistance in nonalcoholic fatty liver disease by triggering sirt1/nf-κb pathway |
topic | Basic Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10473922/ https://www.ncbi.nlm.nih.gov/pubmed/37664157 http://dx.doi.org/10.3748/wjg.v29.i31.4744 |
work_keys_str_mv | AT yanbaofei huangqindecoctionalleviateslipidmetabolismdisordersandinsulinresistanceinnonalcoholicfattyliverdiseasebytriggeringsirt1nfkbpathway AT panlanfen huangqindecoctionalleviateslipidmetabolismdisordersandinsulinresistanceinnonalcoholicfattyliverdiseasebytriggeringsirt1nfkbpathway AT quanyifang huangqindecoctionalleviateslipidmetabolismdisordersandinsulinresistanceinnonalcoholicfattyliverdiseasebytriggeringsirt1nfkbpathway AT shaqian huangqindecoctionalleviateslipidmetabolismdisordersandinsulinresistanceinnonalcoholicfattyliverdiseasebytriggeringsirt1nfkbpathway AT zhangjingzheng huangqindecoctionalleviateslipidmetabolismdisordersandinsulinresistanceinnonalcoholicfattyliverdiseasebytriggeringsirt1nfkbpathway AT zhangyifeng huangqindecoctionalleviateslipidmetabolismdisordersandinsulinresistanceinnonalcoholicfattyliverdiseasebytriggeringsirt1nfkbpathway AT zhoulibing huangqindecoctionalleviateslipidmetabolismdisordersandinsulinresistanceinnonalcoholicfattyliverdiseasebytriggeringsirt1nfkbpathway AT qianxilong huangqindecoctionalleviateslipidmetabolismdisordersandinsulinresistanceinnonalcoholicfattyliverdiseasebytriggeringsirt1nfkbpathway AT guxiaomei huangqindecoctionalleviateslipidmetabolismdisordersandinsulinresistanceinnonalcoholicfattyliverdiseasebytriggeringsirt1nfkbpathway AT lifengtao huangqindecoctionalleviateslipidmetabolismdisordersandinsulinresistanceinnonalcoholicfattyliverdiseasebytriggeringsirt1nfkbpathway AT wangting huangqindecoctionalleviateslipidmetabolismdisordersandinsulinresistanceinnonalcoholicfattyliverdiseasebytriggeringsirt1nfkbpathway AT liujia huangqindecoctionalleviateslipidmetabolismdisordersandinsulinresistanceinnonalcoholicfattyliverdiseasebytriggeringsirt1nfkbpathway AT zhengxian huangqindecoctionalleviateslipidmetabolismdisordersandinsulinresistanceinnonalcoholicfattyliverdiseasebytriggeringsirt1nfkbpathway |